IMR Press / FBL / Volume 11 / Issue 1 / 10.2741/1836

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma
Show Less
1 G. Rummo” Hospital, Department of Oncology, via Dell’Angelo 1, 82100, Benevento, Italy
2 National Cancer Institute, G. Pascale” foundation, Division of Diagnostic and Interventional Radiology, via M. Semmola, 80131, Naples, Italy
3 National Cancer Institute , G Pascale foundation , Division of Immunology , via M. Semmola, 80131 , Naples, Italy
4 National Cancer Institute, G. Pascale” foundation, Division of Medical Oncology B, via M. Semmola, 80131, Naples, Italy
5 S. Maria delle Grazie Hospital, Department of Oncoematology, Pozzuoli, Naples, Italy
6 A.R.C.O., Medical Oncology, Agnano, Naples, Italy
Academic Editor:Antonio Giordano
Front. Biosci. (Landmark Ed) 2006, 11(1), 782–787;
Published: 1 January 2006
(This article belongs to the Special Issue Gene targets for modulating cell growth)
Abstract

The present study was conducted to evaluate activity and toxicity of the FLEC (folinic acid 100 mg/m2; 5-fluorouracil 1000 mg/m2; carboplatin 300 mg/m2; epirubicin 60 mg/m2) schedule as second-line treatment for progressive locally advanced or metastatic pancreatic cancer (LAMPC). FLEC was administered every 3 weeks with an angiographic catheter introduced into the tumor vascular bed. Thirty-two patients were enrolled. Twenty patients had a PS of 2. Twenty-five patients had metastatic disease to liver. Seven (21.9%) partial responses were observed (WHO criteria). Fifteen patients (46.9%) had stable disease and ten patients (31.2%) had progressive disease. The median OS from the diagnosis was 11.8 months. PS (p=0.0308) and pain (WHO scale, p=0.0222; analogic scale, p=0.0446) significantly improved after therapy. No patient discontinued treatment because of toxicity (NCI-CTC criteria). The current study shows that intraarterial chemotherapy is a good therapeutic option in second-line treatment of LAMPC.

Share
Back to top